Similarly, TP53 co-alterations were associated with lower ORRs in a cohort of patients with urothelial carcinoma and FGFR3 alterations treated with erdafitinib under real-world conditions40; however, in the FIGHT-201 study in FGFR-altered bladder cancer28, baseline concurrent TP53 alterations did not correlate with response or nonresponse to pemigatinib, cautioning against overgeneralization of subgroup analyses. This evidence concerns the gene TP53 and urothelial carcinoma.